John M. Burke, MD, Rocky Mountain Cancer Centers

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers

December 10th 2024

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

Evolving Therapies in R/R DLBCL: Concluding Remarks

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

R/R DLBCL: Novel Therapies in the Pipeline

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 26th 2021

Treating Primary Refractory DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

Bridging Therapy in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 19th 2021

R/R DLBCL: Transplants in the Era of CAR-T

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 12th 2021

CAR T for R/R DLBCL: Safety/Tolerability

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Understanding the CAR-T Process: Collection Through Infusion

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

March 5th 2021

Treating R/R DLBCL With CAR-T: Current Barriers

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

CAR-T Treatment Options for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 26th 2021

CAR T-Cell Therapy for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

Novel Therapies for R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 19th 2021

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

Tafasitamab Combined With Lenalidomide in R/R DLBCL

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 12th 2021

R/R DLBCL: Second-Line Treatment Options

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

February 5th 2021

DLBCL: Treatment Considerations for Challenging Populations

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

DLBCL: Circumstances for Deviating Away From R-CHOP

ByIan Flinn, MD, PhD, Sarah Cannon Research Institute,John M. Burke, MD, Rocky Mountain Cancer Centers,Kami Maddocks, MD, The Ohio State University,Amitkumar Mehta, MD, O'Neal Comprehensive Cancer Center at UAB,Loretta J. Nastoupil, MD, MD Anderson Cancer Center

January 29th 2021

Treatment of R/R DLBCL: Beyond CAR T Therapy

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

RE-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

L-MIND Study in R/R DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

ByJohn M. Burke, MD, Rocky Mountain Cancer Centers,Julio Chavez, MD, Moffitt Cancer Center,Nathan H. Fowler, MD, MD Anderson Cancer Center,Grzegorz S. Nowakowski, MD, Mayo Clinic

September 22nd 2020

Future Directions in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Novel Therapies for CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

PI3 Kinase Inhibitors in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Therapeutic Sequencing in CLL

ByWilliam Wierda, MD, PhD, MD Anderson Cancer Center,John Allan, MD, Weill Cornell Medicine,John M. Burke, MD, Rocky Mountain Cancer Centers,Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center,Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center

July 30th 2020

Articles by John M. Burke, MD, Rocky Mountain Cancer Centers

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

Evolving Therapies in R/R DLBCL: Concluding Remarks

R/R DLBCL: A Glance at Using Novel Therapies Moving Forward

R/R DLBCL: Novel Therapies in the Pipeline

Treating Primary Refractory DLBCL

Bridging Therapy in R/R DLBCL

R/R DLBCL: Transplants in the Era of CAR-T

CAR T for R/R DLBCL: Improving Access and Utilization

CAR T for R/R DLBCL: Safety/Tolerability

Understanding the CAR-T Process: Collection Through Infusion

Treating R/R DLBCL With CAR-T: Current Barriers

CAR-T Treatment Options for R/R DLBCL

CAR T-Cell Therapy for R/R DLBCL

Novel Therapies for R/R DLBCL

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

Tafasitamab Combined With Lenalidomide in R/R DLBCL

R/R DLBCL: Second-Line Treatment Options

DLBCL: Treating Patients Following Relapse on Frontline Therapy

DLBCL: Treatment Considerations for Challenging Populations

DLBCL: Circumstances for Deviating Away From R-CHOP

Treatment of R/R DLBCL: Beyond CAR T Therapy

Phase 2B SADAL Trial in R/R DLBCL

RE-MIND Study in R/R DLBCL

L-MIND Study in R/R DLBCL

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

Standard of Care for Relapsed/Refractory DLBCL

Future Directions in CLL

Novel Therapies for CLL

PI3 Kinase Inhibitors in CLL

Therapeutic Sequencing in CLL

Latest Updated Articles

Trending on OncLive

AI Finds New Applications in Oncologic Surgery, Drug and Biomarker Screening, and Clinical Trial Design

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

Dana-Farber Investigators Report Promising Results from Phase 2 Study of Targeted Therapy for Rare Bile Duct Cancer